异基因造血干细胞移植患者巨细胞病毒感染预防与治疗的研究进展

Progress in prevention and treatment of cytomegalovirus infection in patients with allogeneic hematopoietic stem cell transplantation

异基因造血干细胞移植(allo-HSCT)仍然是血液系统恶性疾病有效的治疗手段。巨细胞病毒(CMV)感染是造血干细胞移植后常见的感染并发症之一,也是导致移植受者死亡的主要原因,对移植受者预后、生存有着重大的影响。对于感染CMV的移植患者采取及时有效的预防和治疗显得尤为重要。本文分析了移植后CMV感染的最新预防和治疗措施。通过Pubmed检索平台查找相关文献资料,就allo-HSCT患者巨细胞病毒感染的预防措施及治疗手段的新进展进行阐述。

Allogeneic hematopoietic stem cell transplantation(allo-HSCT)remains an effective treatment for hematological malignancies.Cytomegalovirus(CMV)infection is one of the common Infection complications after hematopoietic stem cell transplantation,and also the main cause of death of transplant recipients,which has a significant impact on the prognosis and survival of transplant recipients.It is particularly important to take timely and effective prevention and treatment for CMV infected transplant patients.This article discusses the latest prevention and treatment of CMV infection after transplantation,and reviews the recent progress in the prevention and drug treatment of CMV infection in allo-HSCT patients by searching the relevant literature through Pubmed.